Ambroxol (cas 18683-91-5) as a pharmacological chaperone for mutant glucocerebrosidase

Add time:09/30/2019    Source:sciencedirect.com

Gaucher disease (GD) is characterized by accumulation of glucosylceramide in lysosomes due to mutations in the GBA1 gene encoding the lysosomal hydrolase β-glucocerebrosidase (GCase). The disease has a broad spectrum of phenotypes, which were divided into three different Types; Type 1 GD is not associated with primary neurological disease while Types 2 and 3 are associated with central nervous system disease. GCase molecules are synthesized on endoplasmic reticulum (ER)-bound polyribosomes, translocated into the ER and following modifications and correct folding, shuttle to the lysosomes. Mutant GCase molecules, which fail to fold correctly, undergo ER associated degradation (ERAD) in the proteasomes, the degree of which is one of the factors that determine GD severity.Several pharmacological chaperones have already been shown to assist correct folding of mutant GCase molecules in the ER, thus facilitating their trafficking to the lysosomes. Ambroxol (cas 18683-91-5), a known expectorant, is one such chaperone. Here we show that ambroxol increases both the lysosomal fraction and the enzymatic activity of several mutant GCase variants in skin fibroblasts derived from Type 1 and Type 2 GD patients.

We also recommend Trading Suppliers and Manufacturers of Ambroxol (cas 18683-91-5). Pls Click Website Link as below: cas 18683-91-5 suppliers

Prev:Original articleThe chaperone activity and toxicity of Ambroxol (cas 18683-91-5) on Gaucher cells and normal mice
Next:Research paperThe biological activity of hydrogen peroxide. VI. Mechanism of the enhancing effects of l-histidine: the role of the formation of a histidine-peroxide adduct and membrane transport)